marketcaparena
Search

    UG

    UNITED GUARDIAN INC

    Company overview

    Market capitalization
    $32.62M
    Employees
    23
    Latest publication
    2026-09-29
    About UNITED GUARDIAN INC

    United-Guardian, Inc. develops, manufactures, sells, and markets specialty cosmetic ingredients, pharmaceutical products, medical lubricants, and sexual wellness ingredients in the United States and internationally. The company offers cosmetic ingredients, including LUBRAJEL, a line of multifunctional hydrogel formulations for personal care and medical products; B-122, a powdered lubricant used in the manufacture of certain cosmetics, such as pressed powders, eyeliners, and rouges, as well as some industrial products; ORCHID COMPLEX, an oil-based extract of orchids; and LUBRASIL II SB, a special formulation of Lubrajel in which silicone oil incorporates into a Lubrajel base. It also provides medical lubricant products for catheter lubrication, medical devices, condom lubrication, and oral care under the Lubrajel brand, including Lubrajel MG, Lubrajel MGL, Lubrajel RRCG, Lubrajel RR, Lubrajel RC, Lubrajel RA, Lubrajel Fluid, Lubrajel LC, Lubrajel BA, and Lubrajel FACO. In addition, the company offers pharmaceutical products comprising RENACIDIN, a prescription to prevent and to dissolve calcifications in urethral catheters; and CLORPACTIN WCS-90, a chlorine-based drug, which is a topical antimicrobial and is also used in urology. Further, it provides sexual wellness ingredient products, which are hydrogel formulations designed to offer sensory enhancement, lubrication, and moisturization, such as Natrajel NT, Natrajel MA, Natrajel ON, and Natrajel TE product lines. United-Guardian, Inc. was founded in 1942 and is based in Hauppauge, New York.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue3,108,267USD2,872,222USD2,961,855USD2,264,261USD2,838,225USD2,481,127USD2,476,709USD3,060,113USD
    Cost Of Revenue1,562,465USD1,447,789USD1,710,105USD1,338,493USD1,340,854USD1,123,076USD1,195,138USD1,408,866USD
    Gross Profit1,545,802USD1,424,433USD1,251,750USD925,768USD1,497,371USD1,358,051USD1,281,571USD1,651,247USD
    Research Development124,395USD115,021USD124,278USD117,104USD107,868USD114,394USD131,065USD111,072USD
    Total Operating Expenses791,677USD781,984USD529,849USD710,696USD801,918USD747,129USD725,195USD702,119USD
    Operating Income754,125USD642,449USD721,901USD215,072USD695,453USD610,922USD556,376USD949,128USD
    Total Other Income Expense Net163,480USD390,688USD96,078USD111,403USD95,149USD97,037USD84,436USD147,157USD
    Income Before Tax917,605USD1,033,137USD817,979USD326,475USD790,602USD707,959USD640,812USD1,096,285USD
    Income Tax Expense189,026USD214,236USD168,403USD58,034USD163,776USD147,064USD137,088USD230,801USD
    Net Income728,579USD818,902USD649,576USD268,441USD626,826USD560,895USD503,724USD865,484USD
    Tax Provision—214,236USD168,403USD58,034USD163,776USD147,064USD137,088USD230,801USD
    Net Income From Continuing Ops—818,902USD649,576USD268,441USD626,826USD560,895USD503,724USD865,484USD
    Ebitda—642,449USD641,213USD353,776USD720,607USD635,952USD582,710USD970,848USD
    Reconciled Depreciation—29,008USD30,715USD27,301USD25,154USD25,030USD26,334USD21,720USD
    Ebit——610,498USD326,475USD695,453USD610,922USD556,376USD949,128USD
    Depreciation And Amortization——30,715USD27,301USD25,154USD25,030USD26,334USD21,720USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue10,545,468USD12,181,971USD10,885,154USD12,698,503USD13,929,629USD10,986,081USD13,599,084USD13,769,401USD
    Cost Of Revenue5,512,528USD5,721,584USD5,479,566USD5,996,376USD5,747,931USD4,872,335USD5,657,353USD5,667,295USD
    Gross Profit5,032,940USD6,460,387USD5,405,588USD6,702,127USD8,181,698USD6,113,746USD7,941,731USD8,102,106USD
    Research Development463,644USD456,779USD463,992USD490,770USD478,642USD451,208USD397,391USD399,517USD
    Unclassified Operating Expenses2,325,948USD2,356,819USD2,078,564USD2,174,127USD2,035,970USD2,026,368USD——
    Total Operating Expenses2,789,592USD2,813,598USD2,542,556USD2,664,897USD2,514,612USD2,477,576USD2,545,766USD2,522,263USD
    Operating Income2,243,348USD3,646,789USD2,863,032USD4,037,230USD5,667,086USD3,636,170USD5,395,965USD5,579,843USD
    Income Before Tax2,643,015USD4,108,457USD3,250,778USD3,227,680USD5,877,925USD4,161,000USD6,030,370USD5,465,854USD
    Income Tax Expense537,277USD857,582USD669,408USD658,168USD1,219,383USD856,022USD1,268,659USD1,113,523USD
    Tax Provision537,277USD857,582USD640,971USD658,168USD1,219,383USD856,022USD1,268,659USD1,113,523USD
    Net Income2,105,738USD3,250,875USD2,581,370USD2,569,512USD4,658,542USD3,304,978USD4,761,711USD4,352,331USD
    Net Income From Continuing Ops2,105,738USD3,250,875USD2,523,136USD2,569,512USD4,658,542USD3,304,978USD4,761,711USD4,352,331USD
    Ebit2,243,348USD3,646,789USD2,863,032USD4,037,230USD5,667,086USD3,636,170USD5,395,965USD5,579,843USD
    Ebitda2,351,548USD3,742,674USD2,968,714USD4,172,626USD5,813,063USD3,801,431USD5,571,775USD5,771,785USD
    Depreciation And Amortization108,200USD95,885USD105,682USD135,396USD145,977USD165,261USD175,810USD191,942USD
    Reconciled Depreciation108,200USD95,885USD106,900USD135,396USD145,977USD165,261USD175,810USD191,942USD
    Total Other Income Expense Net399,667USD461,668USD387,746USD-809,550USD210,839USD524,830USD634,405USD-113,989USD
    Interest Expense———1,619,100USD567,655USD1,214,921USD1,444,620USD227,978USD
    Net Income Applicable To Common Shares———2,569,512USD4,658,542USD3,304,978USD4,761,711USD4,352,331USD
    Non Operating Income Net Other—————524,830USD634,405USD-113,989USD
    Selling General Administrative——————2,148,375USD2,122,746USD
    Interest Income——————634,410USD101,150USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets13,592,579USD12,699,481USD13,108,579USD12,180,345USD13,394,352USD12,763,387USD13,797,335USD13,254,380USD
    Cash And Equivalents2,390,738USD———————
    Cash And Short Term Investments9,593,795USD8,036,243USD8,573,743USD8,304,592USD8,421,125USD8,121,209USD9,398,280USD9,496,385USD
    Short Term Investments7,203,057USD7,300,389USD7,322,646USD7,443,756USD6,652,644USD6,851,997USD7,522,625USD7,054,469USD
    Total Current Assets12,714,767USD11,811,421USD12,201,397USD11,246,893USD12,466,928USD11,691,416USD12,665,551USD12,484,639USD
    Other Current Assets210,884USD1,767,019USD533,002USD371,895USD2,138,309USD515,067USD386,821USD302,693USD
    Total Liabilities1,961,666USD———————
    Total Current Liabilities1,737,315USD1,466,665USD1,669,321USD1,597,909USD1,853,471USD1,927,638USD1,914,469USD1,875,238USD
    Other Current Liabilities1,219,333USD———————
    Total Stockholder Equity11,630,913USD10,902,334USD11,232,012USD10,582,436USD11,462,575USD10,835,749USD11,882,866USD11,379,142USD
    Total Equity Including Noncontrolling Interest11,630,913USD———————
    Deferred Revenue8,135USD———————
    Net Receivables1,690,819USD2,008,159USD1,586,889USD1,161,703USD1,907,494USD1,552,079USD1,428,455USD1,494,167USD
    Inventory1,179,450USD1,320,670USD1,507,763USD1,408,703USD1,531,817USD1,503,061USD1,451,995USD1,191,394USD
    Property Plant Equipment Net877,812USD888,060USD907,182USD8,185,046USD927,424USD934,965USD956,387USD667,548USD
    Accounts Payable499,754USD114,544USD480,791USD244,964USD415,608USD378,250USD425,003USD513,204USD
    Common Stock459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD
    Retained Earnings11,171,481USD10,442,902USD10,772,580USD10,123,004USD11,003,143USD10,376,317USD11,423,434USD10,919,710USD
    Total Liab—1,797,147USD1,876,567USD1,597,909USD1,931,777USD1,927,638USD1,914,469USD1,875,238USD
    Other Current Liab—1,326,480USD1,176,353USD1,134,719USD1,309,231USD1,549,388USD1,489,466USD1,197,725USD
    Capital Stock—459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD
    Cash—735,854USD1,251,097USD860,836USD1,768,481USD1,269,212USD1,875,655USD2,441,916USD
    Current Deferred Revenue—25,641USD12,177USD—128,632USD———
    Net Debt—-735,854USD-1,251,097USD-860,836USD-1,768,481USD-1,269,212USD-1,875,655USD-2,441,916USD
    Property Plant Equipment Gross—8,217,471USD8,207,585USD8,185,046USD8,169,811USD8,152,198USD8,148,590USD7,833,417USD
    Common Stock Shares Outstanding—4,594,319shares4,594,319shares4,594,319shares4,594,319shares4,594,319shares4,594,319shares4,594,319shares
    Non Current Assets Total—888,060USD907,182USD933,452USD927,424USD1,071,971USD1,131,784USD769,741USD
    Non Current Liabilities Total—330,482USD207,246USD0USD78,306USD0USD436,202USD0USD
    Net Working Capital—10,344,756USD10,532,076USD9,648,984USD10,613,457USD9,763,778USD10,751,082USD10,609,401USD
    Unclassified Current Assets—-1,320,670USD——-1,531,817USD———
    Non Currrent Assets Other———-7,269,688USD———-7,165,869USD
    Unclassified Non Current Assets———-7,251,594USD————
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets13,108,579USD13,797,335USD12,922,838USD10,640,335USD12,242,252USD11,920,276USD12,362,812USD12,544,672USD
    Other Current Assets533,002USD386,821USD367,928USD387,074USD192,579USD260,315USD335,766USD360,051USD
    Total Liab1,876,567USD1,914,469USD1,534,256USD1,373,691USD2,420,983USD1,565,969USD1,729,914USD1,619,734USD
    Total Stockholder Equity11,232,012USD11,882,866USD11,388,582USD9,266,644USD9,821,269USD10,354,307USD10,632,898USD10,924,938USD
    Other Current Liab1,176,353USD1,489,466USD1,384,309USD1,343,276USD1,647,965USD1,382,485USD1,271,674USD1,179,354USD
    Common Stock459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD
    Capital Stock459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD459,432USD
    Retained Earnings10,772,580USD11,423,434USD10,929,150USD8,807,212USD9,361,837USD9,894,875USD10,173,466USD10,465,506USD
    Cash1,251,097USD1,875,655USD8,243,122USD830,452USD531,213USD591,444USD1,048,311USD550,135USD
    Cash And Short Term Investments8,573,743USD9,398,280USD9,094,440USD6,483,968USD8,166,676USD8,182,825USD7,915,827USD8,172,331USD
    Total Current Assets12,201,397USD12,665,551USD12,252,713USD9,970,630USD11,583,390USD11,246,611USD11,567,281USD11,687,100USD
    Total Current Liabilities1,669,321USD1,914,469USD1,534,256USD1,373,691USD2,337,761USD1,414,285USD1,343,059USD1,366,151USD
    Current Deferred Revenue12,177USD—15,498USD—190,164USD———
    Net Debt-1,251,097USD-1,875,655USD-8,243,122USD-830,452USD-531,213USD-591,444USD-1,048,311USD-550,135USD
    Short Term Investments7,322,646USD7,522,625USD851,318USD5,653,516USD7,635,463USD7,591,381USD6,867,516USD7,622,196USD
    Net Receivables1,586,889USD1,428,455USD1,566,839USD1,427,576USD1,813,346USD1,387,698USD2,098,411USD1,672,567USD
    Inventory1,507,763USD1,451,995USD1,223,506USD1,672,012USD1,410,789USD1,415,773USD1,217,277USD1,482,151USD
    Accounts Payable480,791USD425,003USD134,449USD30,415USD410,894USD31,800USD71,385USD186,797USD
    Property Plant Equipment Net907,182USD956,387USD619,195USD559,161USD658,862USD673,665USD780,707USD827,925USD
    Property Plant Equipment Gross8,207,585USD8,148,590USD7,715,513USD7,549,797USD7,528,460USD7,433,920USD780,707USD827,925USD
    Common Stock Shares Outstanding4,594,319shares4,594,319shares4,594,319shares4,594,319shares4,594,319shares4,594,319shares4,594,319shares4,581,401shares
    Non Current Assets Total907,182USD1,131,784USD670,125USD669,705USD658,862USD673,665USD795,531USD857,572USD
    Non Current Liabilities Total207,246USD436,202USD435,713USD391,262USD83,222USD151,684USD386,855USD253,583USD
    Net Working Capital10,532,076USD10,751,082USD10,718,457USD8,596,939USD9,245,629USD9,832,326USD10,224,222USD10,320,949USD
    Non Currrent Assets Other—-7,192,203USD-1USD—-83,222USD-151,684USD14,824USD-223,936USD
    Other Assets——1USD110,544USD——14,824USD29,647USD
    Short Term Debt——21,265USD—————
    Net Tangible Assets———9,266,644USD9,821,269USD10,354,307USD10,632,898USD10,924,938USD
    Other Liab————83,222USD151,684USD386,855USD253,583USD
    Deferred Long Term Liab—————151,684USD386,855USD253,583USD
    Accumulated Depreciation—————-6,760,255USD-6,609,818USD-6,448,831USD
    Intangible Assets——————14,824USD—
    Good Will——————14,824USD—
    Accumulated Other Comprehensive Income——————0USD-6,448,831USD
    Unclassified Equity———————5,989,399USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation58,374USD
    Deferred Income Tax17,105USD
    Change To Account Receivables-108,031USD
    Change To Inventory336,313USD
    Change To Liabilities73,348USD
    Change In Working Capital244,200USD
    Operating Cash Flow2,124,531USD
    Capital Expenditures-29,004USD
    Net Investments185,696USD
    Other Investing Activities8,310USD
    Investing Cash Flow165,002USD
    Common Dividends Paid-1,149,892USD
    Financing Cash Flow-1,149,892USD
    Change In Cash1,139,641USD
    End Cash Flow2,390,738USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income818,902USD649,576USD268,441USD626,826USD560,895USD503,724USD865,484USD956,225USD
    Depreciation29,008USD30,715USD27,301USD25,154USD25,030USD26,334USD21,720USD24,120USD
    Other Non Cash Items133,603USD43,876USD-43,774USD-21,062USD-11,364USD55,189USD-48,290USD421USD
    Change To Account Receivables-425,371USD-428,263USD753,327USD-358,929USD-127,396USD70,544USD183,857USD460,254USD
    Change To Inventory192,093USD-101,054USD123,114USD-28,756USD-48,280USD-268,393USD-19,307USD111,604USD
    Change In Working Capital-347,969USD-619,012USD855,433USD-542,987USD-290,872USD-242,746USD458,481USD396,505USD
    Total Cash From Operating Activities604,536USD330,495USD1,011,000USD303,243USD322,080USD269,297USD1,228,704USD1,324,130USD
    Capital Expenditures-9,886USD-22,539USD-15,231USD-17,613USD-3,608USD-315,173USD-30,600USD-65,348USD
    Free Cash Flow594,650USD307,956USD995,770USD285,630USD318,472USD-45,876USD1,198,104USD1,258,782USD
    Investments39,999USD82,305USD-770,109USD206,316USD679,370USD-835,558USD-5,584,304USD7,945USD
    Total Cashflows From Investing Activities30,113USD59,766USD-770,109USD206,316USD679,370USD-835,558USD-5,584,304USD7,945USD
    Total Cash From Financing Activities-1,149,892USD0USD-1,148,537USD-10,290USD-1,607,893USD0USD-1,607,855USD0USD
    Dividends Paid-1,149,892USD0USD-1,148,537USD-10,290USD-1,607,893USD0USD-1,607,855USD0USD
    Change In Cash-515,243USD390,261USD-907,645USD499,269USD-606,443USD-566,261USD-5,963,455USD1,332,075USD
    Begin Period Cash Flow1,251,097USD860,836USD1,768,481USD1,269,212USD1,875,655USD2,441,916USD8,405,371USD7,073,296USD
    End Period Cash Flow735,854USD1,251,097USD860,836USD1,768,481USD1,269,212USD1,875,655USD2,441,916USD8,405,371USD
    Other Cashflows From Investing Activities—-1,318USD-36,456USD—-3,608USD—-117,904USD—
    Other Cashflows From Financing Activities——————-5,584,304USD7,945USD
    Unclassified Financing Cash Flow——————5,584,304USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income2,105,738USD3,250,875USD2,581,370USD2,569,512USD4,658,542USD3,304,978USD4,761,711USD4,352,331USD
    Depreciation108,200USD95,885USD105,682USD135,396USD145,977USD165,261USD175,810USD191,942USD
    Other Non Cash Items-32,324USD-43,527USD-111,486USD1,077,501USD14,454USD-305,746USD-411,793USD341,650USD
    Change To Account Receivables-161,261USD140,714USD-135,872USD385,959USD-431,883USD717,874USD-430,127USD237,173USD
    Change To Inventory-54,976USD-214,281USD465,506USD-290,223USD4,984USD-198,496USD249,874USD-141,628USD
    Change In Working Capital-597,438USD287,485USD509,300USD-1,063,474USD562,766USD664,918USD-182,889USD-155,239USD
    Total Cash From Operating Activities1,966,819USD3,466,251USD3,144,480USD2,525,169USD5,313,277USD3,594,240USD4,476,111USD4,950,412USD
    Capital Expenditures-58,999USD-433,077USD-165,716USD-75,179USD-116,375USD-43,395USD-113,769USD-74,993USD
    Free Cash Flow1,907,820USD3,033,174USD2,978,764USD2,449,990USD5,196,902USD3,550,845USD4,362,342USD4,875,419USD
    Investments234,338USD-7,077,395USD5,861,469USD897,562USD-67,100USD-468,676USD1,185,756USD-233,766USD
    Total Cashflows From Investing Activities175,343USD-7,077,395USD4,727,577USD897,562USD-183,475USD-468,676USD1,071,987USD-308,759USD
    Total Cash From Financing Activities-2,766,720USD-2,756,323USD-459,387USD-3,123,492USD-5,190,033USD-3,582,431USD-5,049,922USD-4,816,239USD
    Dividends Paid-2,766,720USD-2,756,323USD-459,387USD-3,123,492USD-5,190,033USD-3,582,431USD-5,049,922USD-4,816,239USD
    Change In Cash-624,558USD-6,367,467USD7,412,670USD299,239USD-60,231USD-456,867USD498,176USD-174,586USD
    Begin Period Cash Flow1,875,655USD8,243,122USD830,452USD531,213USD591,444USD1,048,311USD550,135USD724,721USD
    End Period Cash Flow1,251,097USD1,875,655USD8,243,122USD830,452USD531,213USD591,444USD1,048,311USD550,135USD
    Other Cashflows From Investing Activities-58,995USD-433,077USD10,000USD37,039USD-116,375USD-43,395USD1,185,760USD-70,789USD
    Stock Based Compensation——48,838USD—————
    Other Cashflows From Financing Activities——4,727,577USD897,562USD-183,475USD-468,676USD1,071,987USD-308,759USD
    Unclassified Financing Cash Flow——-4,727,577USD———-1,071,987USD—
    Change To Liabilities———-570,643USD569,258USD-39,585USD-26,921USD-64,028USD
    Cash And Cash Equivalents Changes—————-456,867USD498,176USD-174,586USD
    Unclassified Investing Cash Flow——————-1,185,760USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31GeographyInternational635,974USD0001171843-26-003276
    Q1 2026Quarterly · 2026-03-31GeographyUnited States2,236,248USD0001171843-26-003276
    Q1 2026Quarterly · 2026-03-31ProductCosmetic Ingredients843,907USD0001171843-26-003276
    Q1 2026Quarterly · 2026-03-31ProductMedical582,991USD0001171843-26-003276
    Q1 2026Quarterly · 2026-03-31ProductPharmaceuticals1,445,324USD0001171843-26-003276
    Q4 2025Quarterly · 2025-12-31GeographyInternational485,581USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States2,476,274USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyInternational2,403,935USD0001171843-26-001973
    FY 2025Yearly · 2025-12-31GeographyUnited States8,141,533USD0001171843-26-001973
    FY 2025Yearly · 2025-12-31ProductIndustrial And Other — Cosmetic Ingredients3,006,522USD0001171843-26-001973
    FY 2025Yearly · 2025-12-31ProductIndustrial And Other — Medical Lubricants2,111,104USD0001171843-26-001973
    FY 2025Yearly · 2025-12-31ProductIndustrial And Other — Pharmaceuticals5,427,842USD0001171843-26-001973
    Q3 2025Quarterly · 2025-09-30GeographyInternational702,795USD0001171843-25-007077
    Q3 2025Quarterly · 2025-09-30GeographyUnited States1,561,466USD0001171843-25-007077
    Q3 2025Quarterly · 2025-09-30ProductCosmetic Ingredients403,401USD0001171843-25-007077
    Q3 2025Quarterly · 2025-09-30ProductMedical630,773USD0001171843-25-007077
    Q3 2025Quarterly · 2025-09-30ProductPharmaceuticals1,230,087USD0001171843-25-007077
    Q2 2025Quarterly · 2025-06-30GeographyInternational491,699USD0001171843-25-005207
    Q2 2025Quarterly · 2025-06-30GeographyUnited States2,346,526USD0001171843-25-005207
    Q2 2025Quarterly · 2025-06-30ProductCosmetic Ingredients896,549USD0001171843-25-005207
    Q2 2025Quarterly · 2025-06-30ProductMedical489,997USD0001171843-25-005207
    Q2 2025Quarterly · 2025-06-30ProductPharmaceuticals1,451,679USD0001171843-25-005207
    Q1 2025Quarterly · 2025-03-31GeographyInternational723,860USD0001171843-26-003276
    Q1 2025Quarterly · 2025-03-31GeographyUnited States1,757,267USD0001171843-26-003276
    Q1 2025Quarterly · 2025-03-31ProductCosmetic Ingredients698,998USD0001171843-26-003276
    Q1 2025Quarterly · 2025-03-31ProductMedical613,671USD0001171843-26-003276
    Q1 2025Quarterly · 2025-03-31ProductPharmaceuticals1,168,458USD0001171843-26-003276
    Q4 2024Quarterly · 2024-12-31GeographyInternational390,653USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States2,086,056USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyInternational2,006,045USD0001171843-26-001973
    FY 2024Yearly · 2024-12-31GeographyUnited States10,175,926USD0001171843-26-001973
    FY 2024Yearly · 2024-12-31ProductIndustrial And Other — Cosmetic Ingredients5,438,262USD0001171843-26-001973
    FY 2024Yearly · 2024-12-31ProductIndustrial And Other — Medical Lubricants2,028,564USD0001171843-26-001973
    FY 2024Yearly · 2024-12-31ProductIndustrial And Other — Pharmaceuticals4,715,145USD0001171843-26-001973
    Q3 2024Quarterly · 2024-09-30GeographyInternational597,417USD0001171843-25-007077
    Q3 2024Quarterly · 2024-09-30GeographyUnited States2,462,696USD0001171843-25-007077
    Q3 2024Quarterly · 2024-09-30ProductCosmetic Ingredients1,289,587USD0001171843-24-006259
    Q3 2024Quarterly · 2024-09-30ProductIndustrial And Other0USD0001171843-24-006259
    Q3 2024Quarterly · 2024-09-30ProductMedical648,519USD0001171843-24-006259
    Q3 2024Quarterly · 2024-09-30ProductPharmaceuticals1,122,007USD0001171843-24-006259
    Q2 2024Quarterly · 2024-06-30GeographyInternational581,968USD0001171843-25-005207
    Q2 2024Quarterly · 2024-06-30GeographyUnited States2,808,237USD0001171843-25-005207
    Q2 2024Quarterly · 2024-06-30ProductCosmetic Ingredients1,419,374USD0001171843-24-004675
    Q2 2024Quarterly · 2024-06-30ProductIndustrial And Other0USD0001171843-24-004675
    Q2 2024Quarterly · 2024-06-30ProductMedical557,167USD0001171843-24-004675
    Q2 2024Quarterly · 2024-06-30ProductPharmaceuticals1,413,664USD0001171843-24-004675
    Q1 2024Quarterly · 2024-03-31ProductCosmetic Ingredients1,876,482USD0001171843-24-002786
    Q1 2024Quarterly · 2024-03-31ProductIndustrial And Other0USD0001171843-24-002786
    Q1 2024Quarterly · 2024-03-31ProductMedical428,139USD0001171843-24-002786
    Q1 2024Quarterly · 2024-03-31ProductPharmaceuticals950,323USD0001171843-24-002786
    FY 2023Yearly · 2023-12-31GeographyInternational2,283,949USD0001171843-25-001611
    FY 2023Yearly · 2023-12-31GeographyUnited States8,601,205USD0001171843-25-001611
    FY 2023Yearly · 2023-12-31ProductCosmetic Ingredients4,132,334USD0001171843-25-001611
    FY 2023Yearly · 2023-12-31ProductIndustrial And Other51,594USD0001171843-25-001611
    FY 2023Yearly · 2023-12-31ProductMedical Lubricants1,750,632USD0001171843-25-001611
    FY 2023Yearly · 2023-12-31ProductPharmaceuticals4,950,594USD0001171843-25-001611
    Q3 2023Quarterly · 2023-09-30ProductCosmetic Ingredients1,197,178USD0001171843-24-006259
    Q3 2023Quarterly · 2023-09-30ProductIndustrial And Other0USD0001171843-24-006259
    Q3 2023Quarterly · 2023-09-30ProductMedical663,947USD0001171843-24-006259
    Q3 2023Quarterly · 2023-09-30ProductPharmaceuticals1,196,393USD0001171843-24-006259
    FY 2022Yearly · 2022-12-31GeographyInternational3,161,379USD0001171843-24-001526
    FY 2022Yearly · 2022-12-31GeographyUnited States9,537,124USD0001171843-24-001526
    FY 2022Yearly · 2022-12-31ProductCosmetic Ingredients5,167,909USD0001171843-24-001526
    FY 2022Yearly · 2022-12-31ProductIndustrial And Other116,826USD0001171843-24-001526
    FY 2022Yearly · 2022-12-31ProductMedical Lubricants2,470,163USD0001171843-24-001526
    FY 2022Yearly · 2022-12-31ProductPharmaceuticals4,943,605USD0001171843-24-001526
    FY 2021Yearly · 2021-12-31GeographyInternational2,770,288USD0001171843-23-001846
    FY 2021Yearly · 2021-12-31GeographyUnited States11,159,341USD0001171843-23-001846
    FY 2021Yearly · 2021-12-31ProductCosmetic Ingredients6,872,714USD0001171843-23-001846
    FY 2021Yearly · 2021-12-31ProductIndustrial And Other150,387USD0001171843-23-001846
    FY 2021Yearly · 2021-12-31ProductMedical Lubricants2,171,204USD0001171843-23-001846
    FY 2021Yearly · 2021-12-31ProductPharmaceuticals4,735,324USD0001171843-23-001846
    FY 2020Yearly · 2020-12-31GeographyInternational2,189,860USD0001171843-22-002061
    FY 2020Yearly · 2020-12-31GeographyUnited States8,796,221USD0001171843-22-002061
    FY 2020Yearly · 2020-12-31ProductCosmetic Ingredients4,274,586USD0001171843-22-002061
    FY 2020Yearly · 2020-12-31ProductIndustrial And Other139,482USD0001171843-22-002061
    FY 2020Yearly · 2020-12-31ProductMedical Product2,052,961USD0001171843-22-002061
    FY 2020Yearly · 2020-12-31ProductPharmaceuticals4,519,052USD0001171843-22-002061
    FY 2018Yearly · 2018-12-31GeographyInternational2,513,884USD0001171843-20-002021
    FY 2018Yearly · 2018-12-31GeographyUnited States10,931,681USD0001171843-20-002021
    FY 2018Yearly · 2018-12-31ProductCosmetic Ingredients7,529,487USD0001171843-20-002021
    FY 2018Yearly · 2018-12-31ProductIndustrial And Other173,217USD0001171843-20-002021
    FY 2018Yearly · 2018-12-31ProductMedical Product2,232,141USD0001171843-20-002021
    FY 2018Yearly · 2018-12-31ProductPharmaceuticals3,510,720USD0001171843-20-002021
    FY 2016Yearly · 2016-12-31GeographyOther Countries2,463,060USD0001171843-17-001709
    FY 2016Yearly · 2016-12-31GeographyUnited States8,313,807USD0001171843-17-001709

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.